TRAIL-triggered CCL2 secretion from TRAIL-resistant cancer cells can drive monocyte polarization to MDSCs and M2-like macrophages, which promotes accumulation of tumor-supportive immune cells in the tumor microenvironment [48]. Here, CCL2 is linked to neoplasm.